Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2023 | The promise of gene therapies in SCD and important practical considerations for these agents

In this video, Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, briefly discusses the excitement surrounding novel gene therapies in sickle cell disease (SCD), highlighting the caution that must be taken with these agents. Dr Hanna also comments on the need to improve accessibility to these potentially transformative therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS